Novo Nordisk’s Fall from Grace: The Perils of Losing the First-Mover Advantage
Just a year ago, in July 2024, Danish pharmaceutical giant Novo Nordisk, the maker of Ozempic and Wegovy, reigned as Europe’s most valuable company, outpacing luxury titan LVMH by over $200 billion. Its market cap had soared to nearly $660 billion by mid-2023, a testament to the global craze for its GLP-1 class drugs, which became a symbol of the fight against obesity. Ozempic, launched in the U.S. in 2017, and its weight-loss sibling Wegovy had catapulted Novo to the forefront of the healthcare industry. But much has changed since then. Recently, the company’s stock plummeted 23% in a single day—the worst one-day drop in its history—after slashing its annual profit and sales forecasts. This dramatic decline raises questions about whether Novo’s first-mover advantage is slipping away, potentially mirroring the fate of once-dominant names like Myspace, BlackBerry, Yahoo Search, Zoom, and Peloton.
|Finance| 1409